世界のコンパニオン診断市場2022-2030

【英語タイトル】GLOBAL COMPANION DIAGNOSTICS MARKET FORECAST 2022-2030

Inkwood Researchが出版した調査資料(INK22SP009)・商品コード:INK22SP009
・発行会社(調査会社):Inkwood Research
・発行日:2022年8月8日
・ページ数:205
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥666,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Inkwood Research社は、世界のコンパニオン診断市場規模が、2022年から2030年の間に年平均13.29%成長すると予測しています。当調査資料は、コンパニオン診断の世界市場を対象に広く調査・分析を行い、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、技術別(in situハイブリダイゼーション、PCR、免疫組織化学、次世代シーケンシング、その他)分析、疾患別(腫瘍、神経疾患、感染症、その他)分析、エンドユーザー別(医薬品&バイオ医薬品会社、リファレンスラボラトリー、その他)分析、製品・サービス別(アッセイキット&試薬、ソフトウェア&サービス)分析、地域別(北米、ヨーロッパ、アジア太平洋、その他地域)分析、競争状況などの内容をまとめました。なお、当書には主要企業として、Arup Laboratories, Biomerieux, Abbott Laboratoriesなどの企業情報が含まれています。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・世界のコンパニオン診断市場規模:技術別
- in situハイブリダイゼーション式コンパニオン診断の市場規模
- PCR式コンパニオン診断の市場規模
- 免疫組織化学式コンパニオン診断の市場規模
- 次世代シーケンシング式コンパニオン診断の市場規模
- その他技術によるコンパニオン診断の市場規模
・世界のコンパニオン診断市場規模:疾患別
- 腫瘍コンパニオン診断の市場規模
- 神経疾患コンパニオン診断の市場規模
- 感染症コンパニオン診断の市場規模
- その他疾患コンパニオン診断の市場規模
・世界のコンパニオン診断市場規模:エンドユーザー別
- 医薬品&バイオ医薬品会社における市場規模
- リファレンスラボラトリーにおける市場規模
- その他エンドユーザーにおける市場規模
・世界のコンパニオン診断市場規模:製品・サービス別
- コンパニオン診断アッセイキット&試薬の市場規模
- コンパニオン診断ソフトウェア&サービスの市場規模
・地域別分析
- 北米のコンパニオン診断市場規模
- ヨーロッパのコンパニオン診断市場規模
- アジア太平洋のコンパニオン診断市場規模
- その他地域のコンパニオン診断市場規模
・競争状況

KEY FINDINGS
The global companion diagnostics market is forecasted to register a CAGR of 13.29% over the estimated years 2022 to 2030. The market’s growth is accredited to the rising number of cancer cases and mortalities, the increasing number of adverse drug reaction cases, and the growing popularity of precision medicines.

MARKET INSIGHTS
Companion diagnostics provide crucial data for patient classification, facilitating the effective and secure usage of related biological or pharmaceutical treatments. Moreover, companion diagnostics also help medical personnel evaluate the benefits as well as risks of therapeutic treatments.
Drugs have been manufactured by pharmaceutical companies through the use of a ‘one size fits all’ approach. However, more than 50% of patients do not respond to some drugs, including cancer therapies. In this regard, personalized medicine is used. In the field of personalized medicine, decisions associated with an individual’s disease’s prevention, diagnosis, and treatment, are primarily guided by their genetic profile. Various molecular biomarkers depicting certain gene variants are also being discovered by virtue of genomic studies.
While the development of diagnostic tests has further encouraged the usage of these biomarkers, presently, it is more convenient to diagnose an illness with such testing methods. Therefore, the surging popularity of precision medicines plays a vital role in fueling the global companion diagnostics market growth.

REGIONAL INSIGHTS
The global companion diagnostics market growth assessment entails the in-depth study of North America, Europe, Asia-Pacific, and Rest of World. North America is set to capture the highest market share during the forecast period. The region’s notable growth is reinforced by the rising focus on democratizing precision medicine for various therapeutic applications and the surging prevalence of chronic diseases, such as diabetes as well as cardiovascular conditions.

COMPETITIVE INSIGHTS
As the global companion diagnostics market is highly emerging and poses escalating lucrative opportunities, the need for companion diagnostics observes robust growth. Furthermore, developing markets have recently acquired the attention of eminent players due to the significant potential present therein.
Some of the top players operating in the market are Arup Laboratories, Biomerieux, Abbott Laboratories, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

❖ レポートの目次 ❖

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING NUMBER OF CANCER CASES AND MORTALITIES
3.1.2. INCREASING POPULARITY OF PRECISION MEDICINES
3.1.3. RISING NUMBER OF ADVERSE DRUG REACTION CASES
3.2. KEY RESTRAINTS
3.2.1. COUNTRY-SPECIFIC REIMBURSEMENT ISSUES
3.2.2. FREQUENT CASES OF LEAKAGE IN COMPANION DIAGNOSTICS FOR ONCOLOGY
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK
5. MARKET BY TECHNOLOGY
5.1. IN SITU HYBRIDIZATION
5.2. POLYMERASE CHAIN REACTION
5.3. IMMUNOHISTOCHEMISTRY
5.4. NEXT GENERATION SEQUENCING
5.5. OTHER TECHNOLOGIES
6. MARKET BY INDICATION
6.1. ONCOLOGY
6.2. NEUROLOGY
6.3. INFECTIOUS DISEASES
6.4. OTHER INDICATIONS
7. MARKET BY END-USER
7.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
7.2. REFERENCE LABORATORIES
7.3. OTHER END-USERS
8. MARKET BY PRODUCTS & SERVICES
8.1. ASSAY KITS AND REAGENTS
8.2. SOFTWARE & SERVICES
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED STATES
9.1.5.2. CANADA
9.2. EUROPE
9.2.1. MARKET SIZE & ESTIMATES
9.2.2. KEY GROWTH ENABLERS
9.2.3. KEY CHALLENGES
9.2.4. KEY PLAYERS
9.2.5. COUNTRY ANALYSIS
9.2.5.1. UNITED KINGDOM
9.2.5.2. GERMANY
9.2.5.3. FRANCE
9.2.5.4. SPAIN
9.2.5.5. ITALY
9.2.5.6. POLAND
9.2.5.7. NETHERLANDS
9.2.5.8. REST OF EUROPE
9.3. ASIA-PACIFIC
9.3.1. MARKET SIZE & ESTIMATES
9.3.2. KEY GROWTH ENABLERS
9.3.3. KEY CHALLENGES
9.3.4. KEY PLAYERS
9.3.5. COUNTRY ANALYSIS
9.3.5.1. CHINA
9.3.5.2. JAPAN
9.3.5.3. INDIA
9.3.5.4. SOUTH KOREA
9.3.5.5. INDONESIA
9.3.5.6. SINGAPORE
9.3.5.7. AUSTRALIA & NEW ZEALAND
9.3.5.8. REST OF ASIA-PACIFIC
9.4. REST OF WORLD
9.4.1. MARKET SIZE & ESTIMATES
9.4.2. KEY GROWTH ENABLERS
9.4.3. KEY CHALLENGES
9.4.4. KEY PLAYERS
9.4.5. REGIONAL ANALYSIS
9.4.5.1. LATIN AMERICA
9.4.5.2. MIDDLE EAST & AFRICA
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.2. COMPANY PROFILES
10.2.1. ABBOTT LABORATORIES
10.2.2. AGILENT
10.2.3. ALAMC GROUP
10.2.4. ARUP LABORATORIES
10.2.5. BIOCARTIS
10.2.6. BIOMERIEUX SA
10.2.7. DANAHER CORPORATION
10.2.8. GE HEALTHCARE
10.2.9. GENOMIC HEALTH
10.2.10. ILLUMINA INC
10.2.11. MYRIAD GENETICS INC
10.2.12. QIAGEN NV
10.2.13. ROCHE DIAGNOSTICS
10.2.14. SYSMEX CORPORATION
10.2.15. THERMO FISHER SCIENTIFIC INC



★調査レポート[世界のコンパニオン診断市場2022-2030] (コード:INK22SP009)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のコンパニオン診断市場2022-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆